Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation

Yoshinori Okada, Yuji Matsumura, Kazuyoshi Shimada, Tetsu Sado, Takeshi Oyaizu, Takafumi Sugawara, Yasushi Matsuda, Yasushi Hoshikawa, Hiroto Takahashi, Masami Sato, Takashi Kondo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Tranilast is an anti-allergic agent known to inhibit the release of histamine, interleukin-1β, transforming growth factor β1, and platelet-derived growth factor from various cells and currently is used to treat allergic diseases, keloids, and hypertrophic scars. We evaluated the ability of tranilast to inhibit the development of obliterative airway disease (OAD) in a rat model of heterotopic tracheal transplantation. Methods We transplanted tracheal segments from donor rats (Brown Norway) into subcutaneous pouches in major histocompatibility complex-incompatible recipient rats (Lewis). At Days 21 and 28 after transplantation, we histologically assessed the harvested allografts scored the degree of OAD, on a scale from zero to 4 as previously described, caused by fibroproliferative tissue. Results Recipient animals treated orally with 400 mg/kg/day tranilast throughout the experiment showed significantly decreased OAD compared with control animals, with a histologic score of 1.1 ± 0.4 vs 3.0 ± 1.3, respectively (mean ± SD, p = 0.007), at Day 21 after transplantation and 2.0 ± 1.4 vs 3.9 ± 0.4, respectively (mean ± SD, p = 0.017), at Day 28 after transplantation. Conclusion These results showed that treatment with tranilast significantly decreased fibroproliferative airway changes associated with allograft rejection in a rat model of tracheal transplantation, suggesting that tranilast may be useful in preventing bronchiolitis obliterans after lung transplantation.

Original languageEnglish
Pages (from-to)1392-1395
Number of pages4
JournalJournal of Heart and Lung Transplantation
Volume23
Issue number12
DOIs
Publication statusPublished - 01-12-2004

Fingerprint

Heterotopic Transplantation
Anti-Allergic Agents
Transplantation
Allografts
Bronchiolitis Obliterans
Hypertrophic Cicatrix
Keloid
Lung Transplantation
Histamine Release
Platelet-Derived Growth Factor
Transforming Growth Factors
Major Histocompatibility Complex
Interleukin-1
tranilast

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Okada, Yoshinori ; Matsumura, Yuji ; Shimada, Kazuyoshi ; Sado, Tetsu ; Oyaizu, Takeshi ; Sugawara, Takafumi ; Matsuda, Yasushi ; Hoshikawa, Yasushi ; Takahashi, Hiroto ; Sato, Masami ; Kondo, Takashi. / Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation. In: Journal of Heart and Lung Transplantation. 2004 ; Vol. 23, No. 12. pp. 1392-1395.
@article{feecca4c4bbc4fb18338f9cd761a6a39,
title = "Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation",
abstract = "Background Tranilast is an anti-allergic agent known to inhibit the release of histamine, interleukin-1β, transforming growth factor β1, and platelet-derived growth factor from various cells and currently is used to treat allergic diseases, keloids, and hypertrophic scars. We evaluated the ability of tranilast to inhibit the development of obliterative airway disease (OAD) in a rat model of heterotopic tracheal transplantation. Methods We transplanted tracheal segments from donor rats (Brown Norway) into subcutaneous pouches in major histocompatibility complex-incompatible recipient rats (Lewis). At Days 21 and 28 after transplantation, we histologically assessed the harvested allografts scored the degree of OAD, on a scale from zero to 4 as previously described, caused by fibroproliferative tissue. Results Recipient animals treated orally with 400 mg/kg/day tranilast throughout the experiment showed significantly decreased OAD compared with control animals, with a histologic score of 1.1 ± 0.4 vs 3.0 ± 1.3, respectively (mean ± SD, p = 0.007), at Day 21 after transplantation and 2.0 ± 1.4 vs 3.9 ± 0.4, respectively (mean ± SD, p = 0.017), at Day 28 after transplantation. Conclusion These results showed that treatment with tranilast significantly decreased fibroproliferative airway changes associated with allograft rejection in a rat model of tracheal transplantation, suggesting that tranilast may be useful in preventing bronchiolitis obliterans after lung transplantation.",
author = "Yoshinori Okada and Yuji Matsumura and Kazuyoshi Shimada and Tetsu Sado and Takeshi Oyaizu and Takafumi Sugawara and Yasushi Matsuda and Yasushi Hoshikawa and Hiroto Takahashi and Masami Sato and Takashi Kondo",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.healun.2003.09.020",
language = "English",
volume = "23",
pages = "1392--1395",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "12",

}

Okada, Y, Matsumura, Y, Shimada, K, Sado, T, Oyaizu, T, Sugawara, T, Matsuda, Y, Hoshikawa, Y, Takahashi, H, Sato, M & Kondo, T 2004, 'Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation', Journal of Heart and Lung Transplantation, vol. 23, no. 12, pp. 1392-1395. https://doi.org/10.1016/j.healun.2003.09.020

Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation. / Okada, Yoshinori; Matsumura, Yuji; Shimada, Kazuyoshi; Sado, Tetsu; Oyaizu, Takeshi; Sugawara, Takafumi; Matsuda, Yasushi; Hoshikawa, Yasushi; Takahashi, Hiroto; Sato, Masami; Kondo, Takashi.

In: Journal of Heart and Lung Transplantation, Vol. 23, No. 12, 01.12.2004, p. 1392-1395.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-allergic agent tranilast decreases development of obliterative airway disease in rat model of heterotopic tracheal transplantation

AU - Okada, Yoshinori

AU - Matsumura, Yuji

AU - Shimada, Kazuyoshi

AU - Sado, Tetsu

AU - Oyaizu, Takeshi

AU - Sugawara, Takafumi

AU - Matsuda, Yasushi

AU - Hoshikawa, Yasushi

AU - Takahashi, Hiroto

AU - Sato, Masami

AU - Kondo, Takashi

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background Tranilast is an anti-allergic agent known to inhibit the release of histamine, interleukin-1β, transforming growth factor β1, and platelet-derived growth factor from various cells and currently is used to treat allergic diseases, keloids, and hypertrophic scars. We evaluated the ability of tranilast to inhibit the development of obliterative airway disease (OAD) in a rat model of heterotopic tracheal transplantation. Methods We transplanted tracheal segments from donor rats (Brown Norway) into subcutaneous pouches in major histocompatibility complex-incompatible recipient rats (Lewis). At Days 21 and 28 after transplantation, we histologically assessed the harvested allografts scored the degree of OAD, on a scale from zero to 4 as previously described, caused by fibroproliferative tissue. Results Recipient animals treated orally with 400 mg/kg/day tranilast throughout the experiment showed significantly decreased OAD compared with control animals, with a histologic score of 1.1 ± 0.4 vs 3.0 ± 1.3, respectively (mean ± SD, p = 0.007), at Day 21 after transplantation and 2.0 ± 1.4 vs 3.9 ± 0.4, respectively (mean ± SD, p = 0.017), at Day 28 after transplantation. Conclusion These results showed that treatment with tranilast significantly decreased fibroproliferative airway changes associated with allograft rejection in a rat model of tracheal transplantation, suggesting that tranilast may be useful in preventing bronchiolitis obliterans after lung transplantation.

AB - Background Tranilast is an anti-allergic agent known to inhibit the release of histamine, interleukin-1β, transforming growth factor β1, and platelet-derived growth factor from various cells and currently is used to treat allergic diseases, keloids, and hypertrophic scars. We evaluated the ability of tranilast to inhibit the development of obliterative airway disease (OAD) in a rat model of heterotopic tracheal transplantation. Methods We transplanted tracheal segments from donor rats (Brown Norway) into subcutaneous pouches in major histocompatibility complex-incompatible recipient rats (Lewis). At Days 21 and 28 after transplantation, we histologically assessed the harvested allografts scored the degree of OAD, on a scale from zero to 4 as previously described, caused by fibroproliferative tissue. Results Recipient animals treated orally with 400 mg/kg/day tranilast throughout the experiment showed significantly decreased OAD compared with control animals, with a histologic score of 1.1 ± 0.4 vs 3.0 ± 1.3, respectively (mean ± SD, p = 0.007), at Day 21 after transplantation and 2.0 ± 1.4 vs 3.9 ± 0.4, respectively (mean ± SD, p = 0.017), at Day 28 after transplantation. Conclusion These results showed that treatment with tranilast significantly decreased fibroproliferative airway changes associated with allograft rejection in a rat model of tracheal transplantation, suggesting that tranilast may be useful in preventing bronchiolitis obliterans after lung transplantation.

UR - http://www.scopus.com/inward/record.url?scp=19944399085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944399085&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2003.09.020

DO - 10.1016/j.healun.2003.09.020

M3 - Article

VL - 23

SP - 1392

EP - 1395

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 12

ER -